1 Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman.

Slides:



Advertisements
Similar presentations
2008 Johns Hopkins Bloomberg School of Public Health Setting Up a Smoking Cessation Clinic Sophia Chan PhD, MPH, RN, RSCN Department of Nursing Studies.
Advertisements

13 Principles of Effective Addictions Treatment
Low-Income and Blue-Collar Populations Elizabeth Barbeau, ScD, MPH Dana-Farber Cancer Institute Harvard School of Public Health.
Encouraging cessation intervention to become routine practice for people working with Aboriginal and Torres Strait Islander clients Toni Mason Aboriginal.
STAGES OF CHANGE Precontemplation Contemplation Action Maintenance Relapse Not yet considering quitting Thinking about quitting Making a quit attempt Remaining.
Systematic Review of the Effectiveness of health behavior interventions based on TTM.
Community-based Clinical Trials: Site Variation and Adoption of Innovation Dennis McCarty, PhD Allie Buti, MPH Lynn Kunkel, MS, CCRP Holly Fussell, PhD.
Using New Communication Technologies to Enhance Services at Smoking Quitlines Lorien Abroms, ScD. Dept. of Prevention & Community Health GW School of Public.
Integrated Dual Diagnosis Treatment
Basma Y. Kentab MSc. Department of Clinical Pharmacy May 2014.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
The Role of Quitlines in Comprehensive Tobacco Cessation: Where are We Now; Where are We Going; and How do We Get There? Tamatha Thomas-Haase, MPA Manager,
Nicotine Replacement Therapy: Administration and Overview Barbara Hart, MPA and Claudia Lechuga, MS Bronx BREATHES T: (718) E:
Prevention strategies
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Smoking Cessation Pathway Reducing the infant mortality rate in Cincinnati and Hamilton County.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
The Demand for and Supply of Cessation Products & Services Frank J. Chaloupka University of Illinois at Chicago.
Center for Tobacco Research and Intervention University of Wisconsin Medical School Transdisciplinary Tobacco Use Research Centers Treating Tobacco Use.
First RCT of Web-Based Acceptance & Commitment Therapy For Smoking Cessation: 3 Month Processes & Outcomes Jonathan B. Bricker, PhD Fred Hutchinson Cancer.
Smoking Cessation for Pregnancy and Beyond: Virtual Clinic Companion Slides Catherine A. Powers, EdD, LSW PACE – Tobacco Prevention and Cessation Education.
Kenneth E. Warner University of Michigan University of Iowa November 15, 2002 Technology, Policy, and the Future of Nicotine Addiction.
Quittin’ Time: Helping Employees Become Tobacco-free June 2005.
Clinical aspects of smoking cessation Jean-Pierre Zellweger, MD Swiss Lung Association and Int. Union against TB and Lung Disease (The Union)
What we need to know about smoking & tobacco addiction.
University of Texas System Wellness Symposium March , 2007 UTMB – Galveston Employee Health & Wellness Gerald Cleveland, M.A. Director, Employee.
Real-world effectiveness of nicotine replacement therapy in pregnancy Leonie S. Brose, PhD Andy McEwen, PhD & Robert West, PhD University College London.
An Updated Algorithm for Choosing Among Smoking Cessation Treatments John R. Hughes University of Vermont, USA
TOBACCO CONTROL INITIATIVE HCSD Disease Management Program Quarterly Meeting April 26, 2005 Sarah Moody Thomas, PhD Statewide Clinical Lead.
Addressing Tobacco Use within College Health Services National Conference of Tobacco or Health December 12, 2003 – Boston, MA Michael P. McNeil, M.S. Coordinator,
1 David B. Abrams, Ph.D National Conference on Tobacco or Health Dec Boston The Centers for Behavioral & Preventive Medicine Brown Medical School,
Smoke-Free Homes & Smoking Cessation TUS-CPS overlap sample Karen Messer, Ph D Moores UCSD Cancer Center.
Applying Science to Transform Lives TREATMENT RESEARCH INSTITUTE TRI science addiction Mady Chalk, Ph.D Treatment Research Institute CADPAAC Conference.
Seal of Approval Breakthrough Group Patty Mabry, Ph.D. Office of Behavioral and Social Science Reasearch NIH.
PHSB 612: Interventions Diane M. Dowdy, Ph.D. Spring 2008.
Analysis of MDS Data Deborah J. Ossip-Klein, Ph.D. University of Rochester Medical Center 2005 NAQC Annual Membership Meeting Chicago.
Laws/Policies ABSTRACT Problem: A challenge for tobacco control practitioners is getting smokers to quit using cessation methods. To increase the proportion.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Nicotine dependence It’s in ICD 10! MRCPsych addiction psychiatry seminars March 2010.
Tobacco Cessation Strategies and Resources: Epidemiology, Evidence and Availability May 29, 2013 The National Tobacco-Free College Campus Initiative: Building.
Modeling the Effects of Policies and Interventions on Adult Smoking Prevalence David Levy, Ph.D. Dave Abrams, Ph.D. & Patty Mabry, Ph.D. May 3, 2006.
July 2006 Treating Tobacco Use and Dependence. Learning Objectives At the end of this session you should understand: The impact of tobacco dependence.
 1,400 Montanans die a year from a tobacco related disease  In 2009, 16% or approx 118,00 Montana adults were current smokers  In 2009, approx 50,000.
Factors associated with health care providers’ practice of smoking cessation interventions in public health facilities in Kiambu County, Kenya Dr Judy.
NRT & NRT+ Pilot Preliminary Results Gowri Shetty MS, MPH Gita Bewtra MPH.
E of computer-tailored S moking C essation A dvice in P rimary car E ffectiveness Hazel Gilbert, Irwin Nazareth and Richard Morris Department of Primary.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
-Tobacco is the leading preventable cause of disease, disability, and death in the United States (NIDA, 2012). -About 1 in every 5 deaths in the U.S. result.
1 Behaviour change in theory and in real life Robert West University College London Stockholm, April 2008.
1 Recent studies of clinical significance University College London June 2011 Robert West.
Effectiveness of interventions to aid smoking cessation Robert West University College London September 2008.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
Barbara Silver, MA, CTTS, Carol Ripley-Moffitt, MDiv, CTTS, Jillian E. Harris, BASW, Mark Gwynne, MD, Adam Goldstein, MD, MPH Nicotine Dependence Program.
Fax to Assist On-line Training for Certification Sponsored by Maryland Department of Health and Mental Hygiene and University of Maryland Baltimore County.
Smoking Cessation Medication
Dissemination and Implementation Research
screening, brief intervention, and referral to treatment
Assistant professor Family Medicine - Suez Canal University
Meta-analysis of Effectiveness of First-Line Smoking Cessation Pharmacotherapies 6 Months After Quitting Medication Estimated OR (95% CI) Est. abstinence.
Development and Implementation of a Tobacco Cessation Toolkit
Robert West University College London WCTOH Washington 2006
Robert West University College London London March 2008
Behavioural and pharmacological approaches to treating smokers
Get smoker to their baseline for their behavioral health condition and initiating abstinence from substances. Then assess whether, in the past year, was.
Tobacco Cessation Guidelines for COPD
Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman.
David Levy, Ph.D. Dave Abrams, Ph.D. & Patty Mabry, Ph.D. May 3, 2006
Public/Population Health Approach to Substance Abuse Prevention & Treatment Determine the Burden of Substance Abuse and Service Barriers to Develop Plan.
Presentation transcript:

1 Current Evidence-Based Cessation Treatments: Efficacy and Critical Ingredients Saul Shiffman

2 Outcome of Smoking Cessation without Treatment  47% report trying to quit annually  13% of unaided quit efforts don’t last 24 h  Sustained unaided quit rate <3%

Behavioral treatment Pharmacologic treatment

4 Behavioral Treatment  Aimed at assisting behavior change  Practical psycho-educational approach  Based on cognitive-behavioral treatment principles  “Multi-component” mix dominates  Few/no “brand-name” differentiated treatment approaches  Little/no content innovation in 20 years

5 Active Ingredients in Behavioral Programs  Information  Motivation enhancement  Encouragement  Support  Planning & problem- solving  Tips & techniques  Medication support  Process orientation  Structure  Conceptual  Temporal  A specific, step-by-step, pathway to quitting  Contact, engagement, caring  Lifestyle change

6 Effectiveness of Behavioral Treatment Components Source: AHRQ analysis: 2000 * Significantly better than nothing Guess which treatment is no longer in current use

7 More is Better Source: AHRQ analysis: 2000

8 Developments in Behavioral Treatment  Little/no content innovation  Innovations in delivery modality & dissemination  Channels  Media  Providers  Packaging  Duration

9 The Old & New Models of Behavioral Treatment Old wayNew way ApproachCognitive- behavioral MediumFace-2-facePhone, web Delivery model CentralDe-centralized ProviderSemi-ProPara-pro, computer ScriptingAd-libScripted IntensityHighLow-Medium MedicationNegativeIntegrate

10 Some Low-Intensity, Convenient Forms Are Ineffective Source: AHRQ analysis: 2000

11 Effectiveness Rises with Intensity Source: AHRQ analysis: 2000

12 Targeting to Groups  By gender, ethnicity, age, disease, etc, etc  No evidence they require different approaches  Targeted materials may be more appealing  Situations that affect the challenge & need may need different approach  e.g., pregnancy, acute abstinence in hospital

13 Tailoring to Individuals  One size does not fit all  Assess user  Tailor content, emphasis, sequence to individual characteristics and needs  Model what a counselor would do  Greater utilization, satisfaction  Improved efficacy

14 Behavioral treatment Pharmacologic treatment

15 Pharmacological Treatment  Meant to address dependence-related symptoms  Nicotine Replacement Therapy (NRT)  Patch  Gum  Lozenge  Puffer  Nasal spray  Bupropion  New compounds, approaches coming (Frank Vocci) OTC

16 All Medications Effective; About Equally Effective Source: AHRQ analysis: 2000 Studies vary in populations, behavioral intervention, and length of follow-up

17 Combining Medications Enhances Efficacy Source: AHRQ analysis: 2000 No combination approved by FDA gum, puffer, nasal spray

18 Estimated Assisted Quit Attempts (in thousands) Innovation in Dissemination: OTC Marketing Increased Utilization Burton et al, MMWR, 2000 Patch mania OTC switch Zyban intro Nasal Spray

19 Behavioral treatment Pharmacologic treatment

20 Silagy meta-analysis Pharmacological & Behavioral Treatments: Additive Effects Pharm RR = 1.9 Pharm RR = 1.5 Beh RR = 1.7 Beh RR = 1.9

21 Treatment Options: Approximate Effectiveness

22 Impact of Treatment Depends on Utilization Impact (# of quits) = Efficacy (% quit) X Utilization (# using method)

23 Treatment Options: Most Effective are Least Used 72% 11% 7% 8%1% Least effective methods most used

24 Even Among NRT Users Compliance is Poor – and it Matters Average nicotine gum use ~ 4/day

25 Status of Cessation Treatment and Goals for Change Efficacy LowHigh Reach LowPresent High

26 Barriers to Treatment Use Behavioral Tx  Disconnect on mechanism  Don’t see a need  Injury to esteem  Doubt efficacy  Cost  Mostly non-cash Pharmacological Tx  Disconnect on mechanism  Don’t see a need  Injury to esteem  Doubt efficacy  Doubt safety  Cost  Mixed empirical support

27 We Are Reaching Only The Tip of the Iceberg Not currently interested in quitting 56% Interested in quitting, not ready to quit now 26% Preparing to try quitting 13% Actually trying to quit 5% Sources: NHIS 2000, DiClemente et al, 1991 Our Church of Perpetual Abstinence

28 Building Demand  “Build it, they will come”  Marketing: product, positioning, packaging, promotion  Figure out what people want  Explain what it is  Explain why they need it  Make it pleasant, palatable, effective  Make it cool  Different strokes for different folks  Make it, attractive, accessible, & convenient  Promote it (repeatedly)  Maintain a continuing relationship & system of care – not!

NOT!